Sofia 2 SARS Antigen+ FIA; Sofia 2 Lyme FIA
Ortho Clinical Diagnostics Inc. (QuidelOrtho) · Decision date Sep 4, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K254264 on 2026-09-04, covering the Sofia 2 SARS Antigen+ FIA and the Sofia 2 Lyme FIA from Ortho-Clinical Diagnostics, Inc. (QuidelOrtho). The application was received 12/30/2025 under product code QVF, with subsequent product codes KHO and LSR, in the Microbiology specialty. A SESE finding is a 510(k) clearance, not a PMA approval.
The review document describes the SARS-CoV-2 component as a rapid lateral flow immunoassay for qualitative detection of SARS-CoV-2 nucleoprotein in anterior nasal swab specimens, and the Lyme component as a rapid lateral flow immunoassay for differential detection of human IgM and IgG antibodies to Borrelia burgdorferi. The document states that performance characteristics were established from August 2021 to November 2022 and that labeling supports the finding of substantial equivalence. The available excerpts do not give the full intended-use wording, clinical performance figures, or the specific changes that distinguish this submission from its predicate.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Sep 4, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254264
- Regulatory pathway
- 510(k) premarket notification
- Product code
- QVF
- Decision code
- SESE
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings.
- Product code
- QVF
- FDA device class
- 2
FDA decision timeline
K254264 received
Application receipt date recorded by FDA.
K254264 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QVF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| BD Diagnostic Solutions / Becton, Dickinson & Company | 510(k) clearance | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ortho Clinical Diagnostics Inc. (QuidelOrtho)
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- San Diego, CA
Sources and methodology
- Original FDA record: K254264
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records